Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Masimo takes over Tony Stark’s headquarters
Masimo moved its headquarters to a Hollywood-hotspot at 52 Discovery in Irvine, Calif., a location often used in films to represent upscale corporate headquarters.
The rotund glass front entrance has served as a backdrop for multiple Hollywood films, operating as the upscale Stark headquarters in Iron Man, and a central location in Transformers, Dodgeball, and multiple other films and tv shows. Read more
2. Report: Edwards, Align Technology hackers may dodge insider trading beef
Hackers in a ring that stole confidential information from Edwards Lifesciences, Align Technology and others could reportedly dodge insider trading charges because they hacked PR websites rather than the companies they traded in.
Although it appears to be a classic insider trading case – the 2 Ukrainian defendants allegedly used confidential information to reap $30 million in trading profits – because the hackers are charged with stealing the information, rather than as insiders who breached a duty owed to the source of the information, insider trading charges might not apply, the New York Times reports. Read more
1. Diabetes: Intarcia’s implantable drug pump tops Merck’s Januvia
Intarcia Therapeutics unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck’s Januvia.
Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature osmotic pump reduced glycated hemoglobin (HbA1c) levels and weight in patients in the study, the company said. The subcutaneous ITCA 650 is designed to deliver the drug exenatide for 1 year. Read more